A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of off-the-shelf cellular immunotherapies to patients. We have pioneered a therapeutic approach that we generally refer to as cellular programming: we create and engineer human induced pluripotent stem cells (iPSCs) to incorporate novel synthetic controls of cell function; after the engineering step that incorporates multiple functional elements into the iPSCs, we generate a clonal master iPSC line for use as a renewable source of starting material for the manufacture of cell therapies; through the manufacturing process, we direct the fate of the clonal master iPSC line to produce our cell therapy product candidates that are uniform in composition.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -136M | -136M | -186M | -161M | -282M | -212M |
| EPS | $-1.15 | $-1.15 | $-1.64 | $-1.64 | $-2.91 | $-2.24 |
| Free Cash Flow | -112M | -112M | -124M | -138M | -284M | -214M |
| ROIC | -72.7% | -51.8% | -58.4% | -43.7% | -58.2% | -31.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.54 | 0.38 | 0.37 | 0.46 | 0.36 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -148M | -148M | -210M | -191M | -308M | -217M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -65.8% | -51.8% | -58.4% | -43.7% | -58.2% | -31.3% |
| Shares Outstanding | 119M | 119M | 114M | 98M | 97M | 95M |
FATE THERAPEUTICS INC passes 0 of 9 quality checks, indicating weak fundamentals.
FATE THERAPEUTICS INC (FATE) has a 5-year average return on invested capital (ROIC) of -48.7%. This is below average and may indicate limited pricing power.
FATE THERAPEUTICS INC (FATE) has a market capitalization of $155M. It is classified as a small-cap stock.
FATE THERAPEUTICS INC (FATE) does not currently pay a regular dividend.
FATE THERAPEUTICS INC (FATE) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
FATE THERAPEUTICS INC (FATE) generated $-112 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
FATE THERAPEUTICS INC (FATE) has a debt-to-equity ratio of 0.54. This indicates moderate leverage.
FATE THERAPEUTICS INC (FATE) reported earnings per share (EPS) of $-1.15 in its most recent fiscal year.
FATE THERAPEUTICS INC (FATE) has a return on equity (ROE) of -51.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 14 years of financial data for FATE THERAPEUTICS INC (FATE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
FATE THERAPEUTICS INC (FATE) has a book value per share of $1.75, based on its most recent annual SEC filing.